Antibiotic Ketek Trial in Children
One day following a rport in The New York Times, Sanifo-Aventis, manufacturer of Ketek, suspended the trial in children. The FDA has not announced any action.
One day following a rport in The New York Times, Sanifo-Aventis, manufacturer of Ketek, suspended the trial in children. The FDA has not announced any action.
A provocative article by Dr. Joanna Moncrieff and Dr. David Cohen, PLOS Medicine, June 5.
It is difficult to believe this latest announcement laying claim to a new "under treated" psychiatric disorder–Intermittent Explosive Disorder (IED) is not a parody !!
This is documented evidence of major medical malpractice.
The following confirms to us that the U.S. government (specifically, in this case, the FDA) and licensed academic and/or commercial laboratories that test drugs in human subjects have descended into a moral abyss.
A ray of hope that might help cleanse medicine of its corrupt interaction with drug company marketers.
The Journal of Occupational and Environmental Medicine (JOEM) has published a retraction of a 1997 fraudulent article claiming chromium does not cause
cancer.
Two documented news reports provide evidence validating our charge that FDA officials and drug manufacturers.
Informed Consent: The Subject’s Right to Know Here’s what you should ask before you decide to give your informed consent to research. A 1999 report by the Institute of Medicine (IOM), “To Err is Human,” brought to light the magnitude of preventable deaths resulting from medical errors The IOM report indicated that as many as…
“There is a crisis of credibility in medicine and science,” says Dr Joseph Sonnabend who, as a former virologist for the Medical Research Council and a retired Aids physician, has watched the basis for public confidence decline.
An investigative report in The Philadelphia Inquirer examined pharmaceutical company ties to six, tax exempt organziations that identify themselves as “patient advocacy” groups, "Each a leading advocate for patients in a disease area.”
Our criticism of a high risk, speculative drug experiment conducted on healthy children and adolescents at Yale University’s Psychiatric Institute was validated by a federal investigation: and our criticism is now validated by the principle investigator, Dr. Thomas McGlashan.